Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Foghorn Therapeutics Inc. (Nasdaq: FHTX) has announced oral presentations at the 18th Annual Drug Discovery Chemistry Meeting from April 10-13, 2023, in San Diego, CA. The company will share preclinical data on FHD-609, a first-in-class protein degrader of BRD9, currently undergoing Phase 1 clinical trials for synovial sarcoma and SMARCB1-loss tumors. Initial safety and efficacy data is expected mid-2023. Additionally, Foghorn will showcase its innovative platform that targets transcription factors, illustrating how it identifies protein interactions driving disease. The presentation titled Targeting Transcription Factor – BAF Interactions in Cancer will occur on April 13, alongside a presentation on FHD-609's discovery. This meeting emphasizes Foghorn's commitment to developing therapies addressing critical unmet needs in oncology.
- FHD-609 is in Phase 1 trials for treatment of synovial sarcoma and SMARCB1-loss tumors.
- Initial Phase 1 safety and efficacy data expected mid-2023.
- Presentation of innovative preclinical data at a significant industry meeting enhances visibility.
- No revenue or financial metrics presented.
- Dependence on successful outcomes of ongoing clinical trials.
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and protein degradation capabilities at the 18th Annual Drug Discovery Chemistry Meeting. The hybrid meeting will be held April 10–13, 2023, at the Hilton Bayfront in San Diego, CA, and virtually.
The company will present preclinical data on FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, a protein that synovial sarcoma cells rely on for survival. The presentation will also describe the discovery and optimization of this first-in-class clinical compound. FHD-609 is currently in Phase 1 clinical trials for the treatment of synovial sarcoma and SMARCB1-loss tumors. Initial Phase 1 safety and efficacy data is expected in mid-2023.
In addition, Foghorn will present preclinical data showcasing its platform focused on the discovery of new medicines that target the disruption of transcription factors. Foghorn has developed a set of tools to visualize and study the interactions between transcription factors and chromatin remodeling complexes. Using SPI1 as an example, Foghorn will demonstrate how the company is identifying and targeting protein-protein interactions responsible for driving disease within the chromatin regulatory system.
Presentation Details
Title: Targeting Transcription Factor – BAF Interactions in Cancer
Date: Thursday, April 13, 2023
Time: 11:40 a.m. PT
Presenter: Asad M. Taherbhoy, PhD, Director, Drug Discovery, Foghorn Therapeutics
Title: Discovery of FHD-609: A Potent and Selective Heterobifunctional Degrader of BRD9
Date: Thursday, April 13, 2023
Time: 4:55 p.m. PT
Presenter: Matthew Netherton, PhD, Senior Director, Medicinal Chemistry, Foghorn Therapeutics
The slides will be accessible following the presentations under the Science section of the Company’s website.
About FHD-609
FHD-609 is a potent, selective, intravenously administered protein degrader of BRD9, a component of the ncBAF complex. Preclinical studies have demonstrated tumor growth inhibition in synovial sarcoma, a cancer genetically dependent on BRD9. To learn more about this study, please visit ClinicalTrials.gov.
About Synovial Sarcoma
Synovial sarcoma is a rare, often aggressive soft tissue sarcoma that originates from different types of soft tissue, including muscle or ligaments. Synovial sarcoma can occur at any age but is most common among adolescents and young adults. It represents around 5–
About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements concerning the Company’s Phase 1 clinical trials for the treatment of synovial sarcoma and SMARCB1-loss tumors, including the timing of release of clinical data. Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com
Michael Lampe, ScientPR (Media)
michael@scientpr.com
Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com
FAQ
What is the significance of FHD-609 in Foghorn Therapeutics' research?
When will Foghorn Therapeutics present data on FHD-609?
What are the expected outcomes for FHD-609 in clinical trials?
What meeting is Foghorn Therapeutics participating in?
What therapeutic area is FHD-609 targeting?
